BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 132
- Registration Number
- NCT06144697
- Locations
- 🇺🇸
Local Institution - 0003, Austin, Texas, United States
🇺🇸Local Institution - 0001, Anaheim, California, United States
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
- Conditions
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 230
- Registration Number
- NCT06140836
- Locations
- 🇮🇳
Grant Medical Foundation - Ruby Hall Clinic, Pune, Maharashtra, India
🇺🇸Local Institution - 0136, Augusta, Georgia, United States
🇺🇸Local Institution - 0221, Des Moines, Iowa, United States
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2961
- Registration Number
- NCT06133049
- Locations
- 🇺🇸
OptumInsight Life Sciences Inc, Eden Prairie, Minnesota, United States
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2828
- Registration Number
- NCT06126835
- Locations
- 🇺🇸
OptumInsight Life Sciences Inc, Eden Prairie, Minnesota, United States
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 48
- Registration Number
- NCT06122779
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Infinite Clinical Research, Miami, Florida, United States
🇺🇸Local Institution - 0014, Atlanta, Georgia, United States
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 85
- Registration Number
- NCT06112743
- Locations
- 🇵🇱
Local Institution - 0094, Warszawa, Mazowieckie, Poland
🇺🇸Local Institution - 0087, West Hollywood, California, United States
🇺🇸Piedmont Hospital, Atlanta, Georgia, United States
A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in Germany (DELPHIN)
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 550
- Registration Number
- NCT06104644
- Locations
- 🇩🇪
Dermatologische Spezial- und Schwerpunktpraxis Selters, Selters, Rhineland-Palatinate, Germany
🇩🇪Company for Medical Study & Service Selters, Selters, Germany
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
- Conditions
- Interventions
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT06101134
- Locations
- 🇺🇸
Local Institution - 0036, Issaquah, Washington, United States
🇺🇸Local Institution - 0030, Seattle, Washington, United States
🇬🇷Local Institution - 0019, Thessaloniki, B, Greece
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT06094296
- Locations
- 🇺🇸
Local Institution - 0058, Boise, Idaho, United States
🇺🇸Local Institution - 0044, Clermont, Florida, United States
🇺🇸Local Institution - 0049, Houston, Texas, United States
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 273
- Registration Number
- NCT06090539
- Locations
- 🇩🇪
Universitätsklinikum Leipzig, Leipzig, Sachsen, Germany
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States